OA13238A - [1,8]Naphthyridin-2-ones and related compounds forthe treatment of schizophrenia. - Google Patents
[1,8]Naphthyridin-2-ones and related compounds forthe treatment of schizophrenia. Download PDFInfo
- Publication number
- OA13238A OA13238A OA1200600052A OA1200600052A OA13238A OA 13238 A OA13238 A OA 13238A OA 1200600052 A OA1200600052 A OA 1200600052A OA 1200600052 A OA1200600052 A OA 1200600052A OA 13238 A OA13238 A OA 13238A
- Authority
- OA
- OAPI
- Prior art keywords
- piperazin
- butoxy
- naphthyridin
- dihydro
- naphthalen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49737003P | 2003-08-22 | 2003-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA13238A true OA13238A (en) | 2006-12-13 |
Family
ID=34216117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200600052A OA13238A (en) | 2003-08-22 | 2004-08-13 | [1,8]Naphthyridin-2-ones and related compounds forthe treatment of schizophrenia. |
Country Status (36)
Country | Link |
---|---|
US (3) | US7160888B2 (sr) |
EP (1) | EP1660497A1 (sr) |
JP (1) | JP4034811B2 (sr) |
KR (2) | KR100765668B1 (sr) |
CN (1) | CN100422181C (sr) |
AP (1) | AP2006003525A0 (sr) |
AR (1) | AR045386A1 (sr) |
AU (1) | AU2004266191B2 (sr) |
BR (1) | BRPI0413860A (sr) |
CA (1) | CA2538915C (sr) |
CR (2) | CR8254A (sr) |
CU (1) | CU23464B7 (sr) |
EA (1) | EA009645B1 (sr) |
EC (1) | ECSP066391A (sr) |
GE (1) | GEP20084447B (sr) |
GT (1) | GT200500007A (sr) |
HK (1) | HK1091815A1 (sr) |
HN (1) | HN2004000319A (sr) |
IL (1) | IL173439A0 (sr) |
IS (1) | IS8267A (sr) |
MA (1) | MA28003A1 (sr) |
ME (1) | MEP45308A (sr) |
MX (1) | MXPA06002070A (sr) |
MY (1) | MY140693A (sr) |
NL (1) | NL1026892C2 (sr) |
NO (1) | NO20060324L (sr) |
NZ (1) | NZ545078A (sr) |
OA (1) | OA13238A (sr) |
PA (1) | PA8609701A1 (sr) |
PE (1) | PE20051039A1 (sr) |
RS (1) | RS20060129A (sr) |
TN (1) | TNSN06063A1 (sr) |
TW (1) | TWI298327B (sr) |
UA (1) | UA82541C2 (sr) |
WO (1) | WO2005019215A1 (sr) |
ZA (1) | ZA200601526B (sr) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
EP2204363A1 (en) * | 2004-06-08 | 2010-07-07 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission |
MXPA06013944A (es) | 2004-06-08 | 2007-10-08 | Neurosearch Sweden Ab | Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina. |
DK1802573T3 (en) | 2004-10-13 | 2016-12-19 | Teva Pharmaceuticals Int Gmbh | METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE. |
FR2877005A1 (fr) * | 2004-10-22 | 2006-04-28 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
US7511035B2 (en) | 2005-01-25 | 2009-03-31 | Glaxo Group Limited | Antibacterial agents |
WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
WO2006090272A1 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia |
JP4109709B1 (ja) * | 2005-04-01 | 2008-07-02 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 統合失調症の治療のためのテトラヒドロ−ピリドアゼピン−8−オン及び関連化合物 |
AP2007004198A0 (en) * | 2005-04-08 | 2007-10-31 | Pfizer Prod Inc | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
TWI329641B (en) * | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
CN102746298A (zh) | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
CN101300256A (zh) * | 2005-10-31 | 2008-11-05 | 辉瑞产品公司 | 7-[4-(4-萘-1-基-哌嗪-1-基)-丁氧基]-3,4-二氢-1h-[1,8]萘啶-2-酮的结晶盐 |
US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
WO2007116265A1 (en) * | 2006-03-31 | 2007-10-18 | Pfizer Products Inc. | Process for making a tetrahydro-pyridoazepin-8-one compound |
EP2027087A2 (en) | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
WO2008032162A1 (en) * | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
US20100093738A1 (en) * | 2006-10-06 | 2010-04-15 | Basf Se | Fungicidal Compounds and Fungicidal Compositions |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
TW200831498A (en) * | 2006-10-13 | 2008-08-01 | Otsuka Pharma Co Ltd | Heterocyclic compound |
WO2008084324A1 (en) * | 2007-01-04 | 2008-07-17 | Pfizer Products Inc. | Naphthyridinone compound |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
EP2162135A4 (en) * | 2007-05-21 | 2012-02-22 | Reviva Pharmaceuticals Inc | COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS |
CL2008001563A1 (es) * | 2007-05-30 | 2008-10-10 | Wyeth6 3 | Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras. |
US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
EP2245028B1 (en) | 2007-12-18 | 2012-02-22 | Actelion Pharmaceuticals Ltd. | 5-aminocyclylmethyl-oxazolidin-2-one derivatives |
KR101457339B1 (ko) | 2008-07-28 | 2014-11-03 | 지앙쑤 구오후아 인베스트먼트 컴퍼니 리미티드 | 아랄킬 치환된 피페리딘 또는 피페라진 유도체 및 정신분열증 치료를 위한 이의 용도 |
WO2010014666A2 (en) | 2008-07-31 | 2010-02-04 | Senomyx, Inc. | Processes and intermediates for making sweet taste enhancers |
EP2376497B1 (en) | 2008-12-12 | 2013-09-18 | Actelion Pharmaceuticals Ltd. | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
KR101779137B1 (ko) * | 2009-01-23 | 2017-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴리(adp-리보스)폴리머라제(parp) 억제제 |
AU2010217772B2 (en) * | 2009-02-26 | 2014-10-23 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives |
EP3309151A1 (en) * | 2009-06-25 | 2018-04-18 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
NZ603268A (en) | 2010-05-04 | 2015-02-27 | Alkermes Pharma Ireland Ltd | Process for synthesizing oxidized lactam compounds |
AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US9156822B2 (en) | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
WO2012080284A2 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
HRP20240285T1 (hr) | 2011-03-18 | 2024-05-24 | Alkermes Pharma Ireland Limited | Farmaceutski pripravci koji sadrže sorbitan estere |
JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
ES2715562T3 (es) | 2011-12-15 | 2019-06-04 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos de amina secundaria |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
CA2869145A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
CA2872883A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
CN104785295B (zh) * | 2015-03-18 | 2018-03-06 | 杭州创培信息科技有限公司 | 一种高选择性多巴胺铂炭催化剂的制备方法 |
EP3317278B1 (en) | 2015-07-01 | 2021-04-14 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
MX2021001091A (es) | 2015-12-10 | 2022-04-26 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. |
CN106242934A (zh) * | 2016-07-26 | 2016-12-21 | 云南民族大学 | 一种酮的β‑位C‑H键乙酰氧化合成方法 |
US11407753B2 (en) * | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
AU2019232437A1 (en) | 2018-03-07 | 2020-10-08 | Bayer Aktiengesellschaft | Identification and use of ERK5 inhibitors |
JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための化合物 |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
JP7421507B2 (ja) | 2018-06-27 | 2024-01-24 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 |
WO2020033420A1 (en) | 2018-08-07 | 2020-02-13 | Firmenich Incorporated | 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof |
CA3104928A1 (en) | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
CR20220066A (es) | 2019-08-14 | 2022-11-28 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
CR20220104A (es) | 2019-09-12 | 2022-04-20 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
CN115298177A (zh) | 2019-10-11 | 2022-11-04 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
CN114634479A (zh) * | 2020-12-16 | 2022-06-17 | 北京盈科瑞创新药物研究有限公司 | 一种派嗪衍生物、其制备方法及应用 |
WO2022212538A1 (en) * | 2021-03-31 | 2022-10-06 | Blueprint Medicines Corporation | Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2023186023A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州旺山旺水生物医药股份有限公司 | 一类n-取代的喹啉酮化合物、其制备方法和用途 |
CN114805081A (zh) * | 2022-05-20 | 2022-07-29 | 都创(上海)医药开发有限公司 | 一种基于微通道连续流技术快速制备1-萘胺的方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5649361A (en) | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神***病治療剤 |
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JPH07165720A (ja) * | 1988-10-31 | 1995-06-27 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体及び該誘導体を含有する精神***病治療剤 |
HU207310B (en) | 1988-12-02 | 1993-03-29 | Pfizer | Process for producing aryl-piperidine derivatives |
DK0402644T3 (da) | 1989-05-19 | 1996-01-02 | Hoechst Roussel Pharma | N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter |
WO1991000863A1 (en) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
AU690527B2 (en) | 1992-12-17 | 1998-04-30 | Pfizer Inc. | Pyrazoles having CRF antagonist activity |
KR100190730B1 (ko) | 1992-12-17 | 1999-06-01 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸 |
TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
US6765008B1 (en) | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
FR2699918B1 (fr) * | 1992-12-30 | 1995-03-17 | Pf Medicament | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. |
JPH07247271A (ja) * | 1994-01-21 | 1995-09-26 | Otsuka Pharmaceut Co Ltd | 3,4−ジヒドロカルボスチリル誘導体 |
FR2731222A1 (fr) | 1995-03-02 | 1996-09-06 | Pf Medicament | Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments |
JP2900130B2 (ja) * | 1995-03-16 | 1999-06-02 | 大塚製薬株式会社 | カルボスチリル誘導体及び該誘導体を含有する精神***病治療剤 |
JP2987484B2 (ja) * | 1995-03-16 | 1999-12-06 | 大塚製薬 株式会社 | カルボスチリル誘導体の製造方法 |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
WO1997003067A1 (en) | 1995-07-13 | 1997-01-30 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
AU4153496A (en) | 1995-10-20 | 1997-05-07 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
JPH09241161A (ja) | 1996-03-08 | 1997-09-16 | Nippon Shinyaku Co Ltd | 医 薬 |
US5912256A (en) | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
FR2761071B1 (fr) | 1997-03-20 | 1999-12-03 | Synthelabo | Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique |
FR2769912B1 (fr) | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine |
DE19747063A1 (de) * | 1997-10-24 | 1999-04-29 | Basf Ag | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
US6267784B1 (en) | 1998-05-01 | 2001-07-31 | Benz Research And Development Corporation | Intraocular lens and haptics made of a copolymer |
US6844344B2 (en) | 1999-12-20 | 2005-01-18 | Eli Lilly And Company | Benzofuran derivatives |
DE10041574A1 (de) | 2000-08-24 | 2002-03-07 | Merck Patent Gmbh | Chromenonderivate |
WO2002048105A2 (en) | 2000-11-16 | 2002-06-20 | Wyeth | Aryloxy piperidinyl derivatives for the treatment of depression |
GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
SI1399438T1 (sl) | 2001-06-29 | 2006-04-30 | Lundbeck & Co As H | Novi heteroarilni derivati, njihova priprava in uporaba |
GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
TW200507841A (en) | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
-
2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 CA CA2538915A patent/CA2538915C/en not_active Expired - Fee Related
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 EP EP04744287A patent/EP1660497A1/en not_active Withdrawn
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/en active Application Filing
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active IP Right Cessation
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active IP Right Cessation
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
-
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
-
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
- 2006-11-08 HK HK06112251.3A patent/HK1091815A1/xx not_active IP Right Cessation
-
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA13238A (en) | [1,8]Naphthyridin-2-ones and related compounds forthe treatment of schizophrenia. | |
JP5972964B2 (ja) | 抗腫瘍剤としての三環式および四環式ピラゾロ[3,4−b]ピリジン化合物 | |
TW550265B (en) | Substituted pyrido- or pyrimido-containing 6,6-or 6,7-bicyclic derivatives | |
AU2021206809B2 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
CA2787360C (en) | Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors | |
JP5489296B2 (ja) | Janusキナーゼの阻害剤 | |
KR101398772B1 (ko) | Mek 억제제로서 유용한 헤테로시클릭 술폰아미드 유도체 | |
TWI822713B (zh) | 適用於治療或預防與其相關之病症之β-3腎上腺素受體的調節劑 | |
WO2016007731A1 (en) | Imidazopyridines and imidazopyrazines as lsd1 inhibitors | |
WO2011082270A2 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
WO2001042247A1 (fr) | Composes heterotricycliques fusionnes, procede de preparation de ces composes et medicaments contenant ces composes | |
CA2392944A1 (en) | Pyrazolo-pyridine derivatives as ligands for gaba receptors | |
WO2006090272A1 (en) | Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia | |
TW202327605A (zh) | 含哌嗪并環類衍生物、其藥學上可接受的鹽及其製備方法和應用 | |
JP2021011492A (ja) | 4H−ピリド[1,2−a]ピリミジン−4−オン化合物 | |
JP2023545256A (ja) | Crhr2拮抗薬としての3-ヒドロキシオキシインドール誘導体 | |
TW202029963A (zh) | 1,2,3,4-四氫喹㗁啉衍生物及其製備方法和應用 | |
CN102869664A (zh) | 吡唑并嘧啶类激酶抑制剂 |